Dr. Jack West reviews the results of the ARCHER-1050 trial that showed superior efficacy with dacomitinib vs. gefitinib in EGFR mutation-positive NSCLC. Is it too little, too late for dacomitinib, or can it find a place in a crowded first line setting?
Dacomitinib: Dark Horse EGFR TKI Charges into a Crowded First Line Setting for EGFR Mutation-Positive Advanced NSCLC (BMIC-016)
